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Abstract
Introduction: Migrants are overrepresented in the European HIV epidemic. We aimed to understand the barriers and facilita-
tors to HIV testing and current treatment and healthcare needs of migrants living with HIV in Europe.
Methods: A cross-sectional study was conducted in 57 HIV clinics in nine countries (Belgium, Germany, Greece, Italy, The
Netherlands, Portugal, Spain, Switzerland and United Kingdom), July 2013 to July 2015. HIV-positive patients were eligible for
inclusion if they were as follows: 18 years or older; foreign-born residents and diagnosed within five years of recruitment.
Questionnaires were completed electronically in one of 15 languages and linked to clinical records. Primary outcomes were
access to primary care and previous negative HIV test. Data were analysed using random effects logistic regression. Outcomes
of interest are presented for women, heterosexual men and gay/bisexual men.
Results: A total of 2093 respondents (658 women, 446 heterosexual men and 989 gay/bisexual men) were included.
The prevalence of a previous negative HIV test was 46.7%, 43.4% and 82.0% for women, heterosexual and gay/bisexual men
respectively. In multivariable analysis previous testing was positively associated with: receipt of post-migration antenatal care
among women, permanent residency among heterosexual men and identifying as gay rather than bisexual among gay/bisexual
men. Access to primary care was found to be high (>83%) in all groups and was strongly associated with country of residence.
Late diagnosis was common for women and heterosexual men (60.8% and 67.1%, respectively) despite utilization of
health services prior to diagnosis. Across all groups almost three-quarters of people on antiretrovirals had an HIV viral load
<50 copies/mL.
Conclusions: Migrants access healthcare in Europe and while many migrants had previously tested for HIV, that they went on
to test positive at a later date suggests that opportunities for HIV prevention are being missed. Expansion of testing beyond
sexual health and antenatal settings is still required and testing opportunities should be linked with combination prevention
measures such as access to PrEP and treatment as prevention.
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1 | INTRODUCTION
The HIV epidemic in Europe is characterized by a dispropor-
tionate number of infections among migrants. Although foreign
citizens only made up 7% of the population of the European
Union (EU) in 2014 [1], an estimated 37% of new HIV diag-
noses in the EU/European Economic Area (EEA) in 2015 were
among migrants [2]. Late diagnosis is a feature of the HIV epi-
demic among migrants; European surveillance data indicate
that some migrant groups are more than twice as likely to be
diagnosed late than nonmigrants [3].
There are several reasons why migrants are at increased
risk of HIV in Europe. Migrants from countries with a general-
ized HIV epidemic obviously have an increased risk of acquir-
ing HIV before migration, but this risk remains as individuals
migrate into, and become sexually active within, migrant com-
munities where the HIV prevalence is higher than the receiv-
ing country population [4]. Estimates of post-migration HIV
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acquisition are as high as 62% in some populations [5]. In
addition, social inequalities associated with migration (e.g. low
income, unemployment, poor housing) [6], HIV-related stigma
and discrimination, and changes in sexual behaviour may
increase the risk of late diagnosis or HIV infection [7-10].
Controlling the HIV epidemic within Europe is dependent
on ensuring that migrants have prompt access to HIV testing,
antiretroviral therapy (ART) and ongoing healthcare [5,11,12].
Migrant populations are, of course, heterogeneous making it
difficult for policymakers and HIV prevention specialists to
provide interventions and services targeted at specific migrant
sub-groups. Often research in this area focuses on one
migrant population (e.g. Central and Eastern Europeans [13])
or migrants in one country [14]. Most of the available
research has been conducted with heterosexual migrants from
Sub-Saharan Africa [15]. While this reflects the global HIV epi-
demic, the heterogeneity of migrants living with HIV in Europe
[3] rationalizes researching other population groups, particu-
larly migrant gay and bisexual men. In this study we present
the results of the first collaborative European survey examin-
ing the key socio-demographic, behavioural and structural fac-
tors associated with HIV testing and primary care utilization
among migrants living with HIV in Europe. We examine how
these factors differ across gender-related group and present
recommendations for targeted health promotion and interven-
tion development.
2 | METHODS
2.1 | Study design
Full details of the methods used in the aMASE (advancing
Migrant Access to health Services in Europe) Study have been
described elsewhere [16]. A convenience sample was
recruited within 57 clinics across the EuroCoord European
Network of Excellence on HIV Research (www.eurocoord.net).
Data collection took place in nine countries (Belgium, Ger-
many, Greece, Italy, The Netherlands, Portugal, Spain, Switzer-
land and the United Kingdom) between July 2013 and July
2015. Patients were eligible for inclusion if they were (1) HIV
positive, (2) aged 18 years and over, (3) foreign-born and resi-
dent in the country of recruitment for six months or more, (4)
diagnosed within five years of the study date and (5) able to
complete, either alone or supported, a computer-assisted self
or personal interview in any one of the 15 languages available
(Amharic, Arabic, Dutch, English, French, German, Greek, Ital-
ian, Polish, Portuguese, Russian, Turkish, Tigrinya, Spanish and
Somali). In Switzerland, migrants from neighbouring Austria,
France, Germany and Italy were excluded.
Eligible participants were identified through clinic records
and asked to participate by clinicians or recruitment research-
ers. Most participants completed within-questionnaire “tick
box” informed consent; participants in Belgium, Switzerland,
Greece and Germany completed additional separate consent
forms required by local research ethics committees.
The survey instrument was developed by an expert panel
made up of experienced epidemiologists and community rep-
resentatives and covered: socio-demographic characteristics
(including migration history); sexual and HIV risk behaviour;
health service use and experiences of living with HIV. Ques-
tionnaires were matched to clinical records (CD4 cell counts,
viral loads, viral clades, HIV testing history, co-infections,
AIDS-defining illnesses, treatment initiation) using a unique
study number.
The target sample size was 2000 participants (1000 men
and 1000 women) from all clinics. Participants were recruited
from a minimum of two clinics in each of the nine countries,
with each clinic forming a discrete cluster. We assumed the
intra-cluster correlation would be relatively weak (e.g. 0.005),
at least after adjustment for country of residence and other
variables selected into our statistical regression models.
Assuming an average cluster size of 50 participants, the
design effect for the study is 1.25 and hence an overall effec-
tive sample size of approximately 1600. With this effective
sample size outcomes within each gender are estimated to be
within 3.5% across Europe based on a 95% confidence inter-
val, and to be within 10% for each country (even if the
assumed underlying prevalence is 50%, which would minimize
precision).
2.2 | Ethics
Ethical approval was obtained separately in each participating
country. See Additional file 1 for full details.
2.3 | Outcomes and variables of interest
The primary outcome measures were access to primary care
and a previous negative HIV test. Primary care represents
integration into healthcare services, beyond attendance at HIV
clinics. Access to primary care was defined as possession of a
health card (Italy/Spain), regular follow up with the Infectious
Diseases Unit (Greece) or registration with a general practi-
tioner (GP) or family doctor (all other countries) at the time
of survey completion. Participants were asked if they had ever
had a negative HIV test (year and country) and where possi-
ble missing self-reported data were replaced by data from
clinical records. Previous HIV testing was used as a marker of
access to HIV prevention opportunities (e.g. how well mes-
sages promoting frequent HIV testing are reaching migrants
before diagnosis) and analysis of this variable was restricted
to those diagnosed post-migration.
Data are presented by three gender-related groups
(women, heterosexual men and gay/bisexual men) as it was
assumed that the three groups were all likely to be different
with regard to HIV testing history and sexual behaviour. Indi-
viduals who identified as transgender were assumed to form a
distinct group and were subsequently excluded from analysis
due to low numbers.
Participants were grouped according to region of birth
based on United Nations Statistics Division geographic regions
and sub-regions classifications [17].
Individuals were classified as diagnosed “late” if they
were diagnosed with a CD4 cell count <350 cells/mm3
(<200 cells/mm3 for “very late”) and without serological
evidence (e.g. avidity testing) of recent seroconversion.
2.4 | Statistical analysis
We undertook statistical analysis using Stata (version 14.1).
We accounted for the clustering of participants at clinic and
the country level by declaring countries to be strata and
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clinics to be primary sampling units using the complex survey
functions. In descriptive analysis proportions were compared
using a design-based chi-square equivalent test and linear
regression used to compare means.
Associations between the primary outcomes and socio-
demographic/behavioural factors were analysed using logistic
regression, with a random effect for clinics. Initial analysis
showed that access to primary care was unexpectedly very
high in some countries for some gender-related groups (e.g.
100% of women in Italy and The Netherlands). Consequently,
for each group, associations are only explored in countries
where less than 95% of respondents reported access to pri-
mary care.
Factors were first analysed individually (see tables in the
results section for variables included in univariate analysis)
and those factors found to have significant associations with
the primary outcomes (a=0.05) were incorporated into a
regression model using backwards selection from a hierarchy
of groups. That is, covariates were arranged into logical group-
ings (e.g. socioeconomic, sexual behaviour etcetera) with fac-
tors considered least important tested for possible removal
first. Covariate groupings not significant at the 5% level were
discarded (see Table 1). In all models, a priori factors (country
of residence, age, region of birth, years since migration, immi-
gration status) were included. Sensitivity analyses were con-
ducted (1) including years since HIV diagnosis as a predefined
factor in the models and (2) excluding respondents who had
migrated from another country in Europe (if that was not the
country of birth). Associations are reported as odds ratios
(OR) and adjusted OR (aOR) with 95% confidence intervals.
Tests for interaction were performed.
3 | RESULTS
Of 3794 patients registered on enrolment logs, 3251 eligible
HIV-positive migrants were invited to participate and 2209
(68%) accepted and completed the survey. Participation was
higher in men (75%) than in women (64%, p < 0.001), and
decreased with age (83% in people aged 18 to 24 years and
62% in those aged over 64 years, p = 0.04). Those born in
Oceania and North America (Rest of World) were most likely
to participate compared with those born in Africa or Europe
(91.3% vs. 62.4% vs. 64.4%, respectively, p < 0.001).
In total, 2117 respondents (658 women, 1435 men and 24
transgender) with matching clinical records were available for
analysis. The 24 transgender participants were excluded from
analysis leaving a final sample of 2093 subjects. Respondents
were from 152 different countries: 35.1% Africa; 31.6% Latin
America & Caribbean and 23.0% Europe (Table 2. See Figures
S1 and S2 in Additional file 2 for full data). A large proportion
of the sample were men (1435/2093; 68.6%) of which 68.9%
(989/1435) were men who described their sexual orientation
as gay or bisexual; there were differences between the three
gender-related groups in nearly all demographic characteris-
tics (Table 2). The majority of women and heterosexual men
were born in Africa compared with gay/bisexual men (63.1%
vs. 57.0% vs. 7.4%, p < 0.001) who were more likely to have
been born in Latin America/Caribbean (18.2% vs. 16.1% vs.
46.1%, p < 0.001). Median times in Current Country of
Residence (CCOR) were 7, 10 and 9 years for women,
heterosexual men and gay men respectively. Other notable
socio-demographic differences were in education level,
employment status, income and immigration status with
Table 1. Covariate groupings of factors significant in univariate analysis for each primary outcome, tested in multivariate analysis in
decreasing order of importance (1 = most important)
Previous negative testing for HIV Access to primary care
Women
1. Country of residence, Age, Region of birth, Years in current
country of residence, Immigration statusa
1. Country of residence, Age, Region of birth, Years in current country of
residence, Immigration statusa
2. Antenatal service attendance in the 2 years prior to
diagnosis*children
2. Employment
3. Number of lifetime sexual partners & Diagnosed with
STI before HIV diagnosis
3. Any health service attendance in two years before diagnosis
4. Education level
Heterosexual men
1. Country of residence, Age, Region of birth, Years in
current country of residence, Immigration statusa
1. Country of residence, Age, Region of birth, Years in current country
of residence, Immigration statusa
2. Number of children cared for in the home 2. Employment
3. Experience of hunger in past 4 weeks
Gay/Bisexual men
1. Country of residence, Age, Region of birth, Years in
current country of residence, Immigration statusa
1. Country of residence, Age, Region of birth, Years in current country of
residence, Immigration statusa
2. Number of sexual partners in current country of residence 2. Currently on ART
3. Diagnosed with an STI before HIV diagnosis 3. Any health service attendance in 2 years before diagnosis
4. Sexual orientation 4. Employment & Income
5. Employment & Income
aPreselected covariates included in all models. Groupings and order of importance based on a priori assumptions informed by expert insight.
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gay/bisexual men more likely to report paid work, higher earn-
ings, higher levels of education and more than three-quarters
(78.8%) reporting permanent residency compared with 51.5%
of women and 58.4% of heterosexual men (Table 2).
3.1 | Access to testing and care pre-diagnosis
Table 3 shows HIV testing history and clinical characteristics
of respondents at the time of diagnosis. Late (or very late)
Table 2. Socio-demographic characteristics of survey respondents, by gender (men separated by sexual orientation)
Women Heterosexual men Gay/bisexual men p value
Total number of respondents n (row %) 658 (31.4) 446 (21.3) 989 (47.3)
Median age in years (IQR)a 37 (30.9 to 44.6) 41 (34.3 to 48.4) 35 (29.4 to 41.6)
Region of birtha <0.001
Africa 415 (63.1) 254 (57.0) 73 (7.4)
Latin America/Caribbean 120 (18.2) 72 (16.1) 456 (46.1)
Rest of World 32 (4.9) 39 (8.7) 146 (14.8)
Europe 91 (13.8) 81 (18.2) 314 (31.7)
Mean age in years at migration (SD) 29.3 (9.9) 30.1 (10.0) 26.3 (8.7) <0.001
Median years in CCOR (IQR)a 7 (4.1 to 12.7) 10 (6.1 to 15.0) 9 (4.8 to 13.9)
Ethnicity (n = 1881)b <0.001
Black African/Caribbean 334 (59.5) 205 (51.8) 51 (5.5)
White European 92 (16.4) 69 (17.4) 296 (32.0)
Latin American/Hispanic 39 (7.0) 26 (6.6) 177 (19.2)
Mixed Ethnicity 44 (7.8) 30 (7.6) 204 (22.1)
Other 52 (9.3) 66 (16.7) 196 (21.2)
Education: upper secondary or morea 322 (48.9) 228 (51.1) 802 (81.1) <0.001
Employment status: working full/part timea 276 (41.9) 217 (48.7) 666 (67.3) <0.001
Relationship statusa 0.005
Married/Cohabitating 273 (41.5) 195 (43.7) 352 (35.6)
Single 302 (45.9) 170 (38.1) 513 (51.9)
Living apart relationship/marriage 83 (12.6) 81 (18.2) 124 (12.5)
Has childrena 474 (72.6) 301 (69.2) 97 (9.9) <0.001
Religion of those who attend services (n = 1165)a
Christian (All denominations) 428 (85.8) 235 (76.1) 306 (85.7)
<0.001
Muslim 48 (9.6) 67 (21.7) 13 (3.6)
Other 23 (4.6) 7 (2.3) 38 (10.6)
Sexual orientation (n = 2076)a <0.001
Gay/Lesbian 12 (1.8) 0 (0.0) 843 (85.2)
Heterosexual 616 (94.5) 417 (95.9) 0 (0.0)
Bisexual 14 (2.1) 0 (0.0) 146 (14.8)
Other 10 (1.5) 18 (4.1) 0 (0.0)
Monthly income compared to national minimum wage (n = 1975)a <0.001
More or a lot more 65 (10.6) 60 (14.3) 430 (45.6)
About the same 82 (13.4) 70 (16.7) 167 (17.7)
Less than minimum wage 215 (35.0) 126 (30.1) 189 (20.1)
Own wage not earned 236 (38.4) 148 (35.3) 140 (14.7)
Not known 16 (2.6) 15 (3.6) 16 (1.7)
Moderate/severe household hunger in past 4 weeks (n = 2006)a 136 (21.8) 112 (26.8) 124 (12.8) <0.001
Immigration status (n = 2078)a <0.001
Permanent residency permit 335 (51.5) 258 (58.4) 777 (78.8)
Temporary residency permit 238 (36.6) 147 (33.3) 152 (15.4)
Asylum seeker/Refugee status 77 (11.8) 37 (8.4) 57 (5.8)
Unknown 58 (8.9) 23 (2.2) 48 (4.9)
Travelled back to country of birth in past year 191 (29.0) 133 (29.8) 497 (50.3) <0.001
Data are n (%), median (Inter-quartile range) or mean (Standard Deviation). N = 2093 unless otherwise stated.
aTested as an independent predictor in univariate analysis for both outcomes.
bExcludes Portugal due to restrictions on data collection. CCOR=Current Country of Residence.
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HIV diagnosis was a feature in all groups (50.0% of women,
56.9% of heterosexual men and 29.8% of gay/bisexual men
were diagnosed late); most respondents were diagnosed post-
migration, with median times to diagnosis five, eight and seven
years for women, heterosexual men and gay men respectively
(Table 3). Health service attendance in the two years prior to
diagnosis was high (>70%) in all groups but less than a quar-
ter of women, 26% of heterosexual men and 38.9% of gay/
bisexual men recalled HIV testing being mentioned/discussed
at that time. Of those who had visited a GP before being diag-
nosed, only 11.4% of women, 21.0% of men and 28.6% of
gay/bisexual men recalled being offered an HIV test. Recollec-
tions of provider-initiated HIV test discussions in sexual health
clinics were higher: 66% of women, 69.6% of heterosexual
men and 73.2% of gay/bisexual men. Less than half of women
recalled being offered a test in antenatal care (Table 3).
There were high rates (82.8%) of previous negative testing
among migrant gay/bisexual men, but less than half of women
and heterosexual men (46.9% and 43.9%, respectively)
reported ever having had a negative test (Table 3).
Among women, those who received antenatal care in CCOR
(post-migration) were three times as likely to have had a pre-
vious negative test (aOR 3.21 95% CI 1.55 to 6.66) than par-
ous women who had not received antenatal care post-
migration (Table 4). Multivariable analysis among heterosexual
men found previous negative testing was significantly
Table 3. Characteristics of survey respondents by gender (men separated by sexual orientation) at time of diagnosis
Women Heterosexual men Gay/bisexual men
Median age in years at diagnosis (IQR) 34 (28.4 to 41.8) 38 (31.7 to 45.7) 34 (28.4 to 41.8)
Median CD4 cell count at diagnosis (IQR) (n = 15)a 277 (124 to 438) 240 (85 to 409) 450 (276 to 639)
Late diagnosis (n = 1815)a,b,c
Diagnosed <350 cells mm3 293 (50.0) 227 (56.9) 248 (29.8)
Diagnosed <200 cells mm3 173 (29.5) 148 (37.1) 110 (13.3)
Median years between migration to CCOR and diagnosis (n = 1859)a 5 (1 to 10) 8 (3 to 13) 7 (3 to 12)
Diagnosed in CCOR (n = 2081)c 598 (91.7) 416 (93.9) 864 (87.6)
AIDS defining illness within 3 months of diagnosis (n = 1997) 101 (16.0) 86 (20.5) 63 (6.7)
<1 year between negative test and diagnosis (n = 1315) 21 (6.8) 18 (9.5) 181 (22.2)
Attended health services in the 2 years prior to diagnosis (n = 1878)a,c 423 (70.7) 310 (74.5) 717 (83.0)
Can recall mention of HIV testing at health service before
diagnosis (n = 1448)a,c
105 (24.8) 81 (26.3) 279 (38.9)
Place where offered HIV test before diagnosisa
Antenatal (n = 55) 26 (49) – –
Inpatient (n = 255) 24 (29.6) 13 (22.4) 24 (27.9)
Emergency (n = 322) 5 (5.7) 5 (6.9) 13 (8.0)
Sexual health clinic or HIV testing clinic (n = 257) 14 (66.7) 16 (69.6) 156 (73.2)
Outpatient (n = 317) 15 (15.2) 15 (23.8) 35 (22.6)
GP/family doctor (n = 690) 23 (11.4) 32 (21.3) 97 (28.6)
Other services (n = 143) 14 (22.6) 9 (33.3) 13 (24.1)
Place of diagnosis (n = 1878)a,c
Antenatal service 74 (12.4) 3 (0.7) 3 (0.3)
Hospital service, e.g. Emergency/Inpatient/Outpatient 240 (40.1) 196 (47.2) 171 (19.8)
Sexual health clinic or HIV testing clinic 75 (12.5) 66 (15.9) 376 (43.5)
GP/Family Doctor 105 (17.5) 95 (22.9) 201 (23.3)
Private clinic 17 (2.8) 7 (1.7) 43 (5.0)
Other 88 (14.7) 48 (11.6) 70 (8.1)
Tested because unwell/health problemsc 261 (39.7) 230 (51.6) 256 (25.9)
Tested because of perceived riskc 128 (19.5) 77 (17.3) 384 (38.8)
Previous self-reported negative HIV test (n = 2028)d 294 (46.7) 183 (43.4) 801 (82.0)
Country of previous negative test (n = 1258)
Current country of residence 128 (44.3) 95 (54.0) 524 (66.1)
Country of birth 145 (50.2) 67 (38.1) 218 (27.5)
Other country 16 (5.5) 14 (8.0) 51 (6.4)
Data are n (%), median (Inter-quartile range) or mean (Standard Deviation). CCOR=Current Country of Residence. N = 2093 unless otherwise
stated.
aIndividuals diagnosed in current country of residence only.
bIndividuals diagnosed with serological evidence of seroconversion (e.g. avidity testing) excluded.
cTested as an independent predictor in univariate analysis.
dData missing from self-report supplemented from clinic records.
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Table 4. Factors associated with self-reported previous HIV-negative testa, among women, heterosexual men and gay or bisexual
men living with diagnosed HIV post-migration and attending HIV clinics in Europe
% (n/N) OR AOR 95% CI p value
Women (N = 565)
Current country of residence (CCOR) 0.233
Belgium 53.8 (50/93) 1.59 1.49 0.72 to 3.10
Greece 29.5 (18/61) 0.57 0.68 0.30 to 1.53
Germany 66.7 (6/9) 3.19 3.21 0.68 to 15.18
Italy 26.1 (6/23) 0.48 0.59 0.19 to 1.86
Netherlands 50.0 (10/20) 1.37 1.79 0.61 to 5.27
Portugal 50.0 (38/76) 1.40 1.49 0.74 to 3.02
Spain 42.3 (60/142) 1.00 1.00 –
Switzerland 44.9 (22/49) 1.04 1.41 0.63 to 3.20
United Kingdom 58.7 (54/92) 1.96 1.76 0.90 to 3.45
Age 0.154
18 to 24 35.1 (13/37) 0.57 0.71 0.32 to 1.57
25 to 34 49.5 (100/202) 1.00 1.00 –
35 to 44 48.4 (90/186) 0.96 0.85 0.54 to 1.33
45 to 54 48.5 (48/99) 0.93 0.81 0.47 to 1.41
55+ 31.7 (13/41) 0.47 0.36 0.16 to 0.80
Region of birth 0.305
Africa 50.6 (176/348) 1.00 1.00 –
Latin America/Caribbean 44.5 (49/110) 0.78 0.79 0.46 to 1.36
Rest of World 28.0 (7/25) 0.38 0.42 0.15 to 1.17
Europe 39.0 (32/82) 0.62 0.73 0.41 to 1.30
Years resident in country 0.050
≤2 41.9 (18/43) 0.70 0.57 0.26 to 1.25
3 to 5 38.0 (57/150) 0.56 0.48 0.28 to 0.82
6 to 10 49.1 (80/163) 0.92 0.82 0.52 to 1.31
>10 52.2 (109/209) 1.00 1.00 –
Immigration status 0.327
Permanent residency 50.7 (151/298) 1.00 1.00 –
Temporary residency 41.7 (70/168) 0.69 0.72 0.46 to 1.13
Refugee/Asylum seeker/Unknown 43.4 (43/99) 0.76 0.77 0.44 to 1.32
Has children 0.006
No children 44.7 (67/150) 1.04 1.00 0.64 to 1.54
Has children, no antenatal care in CCOR 43.9 (161/367) 1.00 1.00 –
Has children, received antenatal care in CCOR 75.0 (36/48) 3.88 3.21 1.55 to 6.66
Heterosexual men (N = 379)
Current country of residence (CCOR) 0.106
Belgium 57.1 (28/49) 1.78 2.51 1.14 to 5.52
Greece 32.0 (16/50) 0.63 0.68 0.30 to 1.55
Germany 25.0 (2/8) 0.44 0.43 0.08 to 2.42
Italyb 0.0 (0/15) – – –
Netherlands 52.6 (10/19) 1.48 2.24 0.79 to 6.33
Portugal 40.0 (16/40) 0.89 0.92 0.42 to 2.04
Spain 42.9 (48/112) 1.00 1.00 –
Switzerland 53.5 (23/43) 1.53 1.41 0.65 to 3.06
United Kingdom 51.7 (30/58) 1.42 1.55 0.76 to 3.14
Age (years) 0.092
18 to 24 30.0 (3/10) 0.39 0.36 0.08 to 1.56
25 to 34 50.5 (47/93) 0.92 0.88 0.50 to 1.56
35 to 44 50.7 (73/144) 1.00 1.00 –
45 to 54 39.4 (37/94) 0.65 0.58 0.33 to 1.00
55+ 34.2 (13/38) 0.54 0.42 0.19 to 0.94
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Table 4. (Continued)
% (n/N) OR AOR 95% CI p value
Region of birth 0.578
Africa 44.2 (91/206) 1.00 1.00 –
Latin America/Caribbean 48.4 (31/64) 1.26 1.32 0.69 to 2.52
Rest of World 38.2 (13/34) 0.82 1.10 0.48 to 2.54
Europe 50.7 (38/75) 1.35 1.55 0.81 to 2.97
Years resident in country 0.428
≤2 50.0 (5/10) 0.98 1.96 0.47 to 8.22
3 to 5 45.5 (25/55) 0.90 1.25 0.60 to 2.60
6 to 10 51.4 (56/109) 1.34 1.54 0.90 to 2.64
>10 42.4 (87/205) 1.00 1.00 –
Immigration status 0.013
Permanent residency 50.0 (117/234) 1.00 1.00 –
Temporary residency 33.7 (29/86) 0.42 0.41 0.23 to 0.75
Refugee/Asylum seeker/Unknown 45.8 (27/59) 0.80 0.55 0.27 to 1.15
Gay or bisexual men (n = 780)
Current country of residence <0.001
Belgium 83.1 (49/59) 1.13 0.65 0.27 to 1.60
Greece 44.4 (20/45) 0.15 0.12 0.05 to 0.29
Germany 50.0 (3/6) 0.26 0.17 0.02 to 1.28
Italyb 0.0 (0/4) 1.00 1.00 –
Netherlands 90.3 (56/62) 1.75 1.33 0.48 to 3.69
Portugal 91.1 (41/45) 1.72 3.41 1.11 to 10.50
Spain 83.8 (299/357) 1.00 1.00 –
Switzerland 78.4 (29/37) 0.66 0.63 0.24 to 1.67
United Kingdom 89.3 (151/169) 1.71 1.06 0.53 to 2.13
Age (years) 0.045
18 to 24 70.6 (48/68) 0.54 0.43 0.22 to 0.85
25 to 34 83.8 (269/321) 1.00 1.00 –
35 to 44 83.6 (219/262) 0.99 0.90 0.54 to 1.51
45 to 54 90.3 (93/103) 1.61 1.87 0.82 to 4.25
55+ 73.1 (19/26) 0.57 1.10 0.33 to 3.62
Region of birth 0.292
Africa 76.9 (40/52) 0.67 1.36 0.54 to 3.40
Latin America/Caribbean 83.3 (319/383) 1.00 1.00 –
Rest of World 81.3 (87/107) 0.84 1.17 0.55 to 2.51
Europe 84.9 (202/238) 1.02 1.84 0.97 to 3.50
Years resident in country 0.128
≤2 90.7 (39/43) 1.65 3.71 1.09 to 12.66
3 to 5 80.3 (118/147) 0.87 1.79 0.90 to 3.53
6 to 10 82.8 (212/256) 0.98 1.13 0.67 to 1.91
>10 83.5 (279/334) 1.00 1.00 –
Immigration status 0.125
Permanent residency 85.4 (527/617) 1.00 1.00 –
Temporary residency 78.1 (89/114) 0.63 0.72 0.38 to 1.37
Refugee/Asylum seeker/Unknown 65.3 (32/49) 0.35 0.44 0.20 to 0.99
Number of sexual partners in current country of residence 0.008
0 to 5 81.3 (109/134) 0.33 0.41 0.18 to 0.93
6 to 10 72.6 (61/84) 0.18 0.32 0.14 to 0.74
11 to 20 81.4 (79/97) 0.33 0.41 0.18 to 0.93
21 to 50 73.4 (94/128) 0.21 0.24 0.12 to 0.49
51 to 100 86.0 (104/121) 0.46 0.46 0.21 to 1.02
More than 100 93.1 (201/216) 1.00 1.00 –
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associated with immigration status, with those with temporary
residency significantly less likely to have had a previous test
than those with permanent residency (aOR 0.41 95% CI 0.23
to 0.75; Table 4) after adjusting for CCOR, age, region of
birth and years since migration. Among gay/bisexual men, neg-
ative testing was significantly associated with: CCOR, age,
total number of sexual partners in CCOR, previous diagnosis
with a sexually transmitted infection and sexual orientation—
with bisexual men being less likely (aOR 0.43 95% CI 0.25
0.74) to have had a previous negative test than gay men
(Table 4). Sensitivity analyses did not indicate that including
the number of years since HIV diagnosis would improve the
multivariable models and did not affect the associations of the
other factors. Sensitivity analysis excluding respondents who
had migrated from another country in Europe (n = 188) did
not appreciably alter the findings.
3.2 | Access to treatment and ongoing care
Most participants in all groups were on antiretroviral treat-
ment and 77.2% of women, 75.9% of heterosexual men and
77.9% of gay/bisexual men on treatment had an undetectable
viral load (<50 copies/mL; Table 5). Most of those not on
treatment reported this was because of their doctor’s advice
or because they were newly diagnosed. Around a third of
women (32.2%) had experienced difficulties with health ser-
vices since migration, a third of whom cited long waiting times
in clinics, 22% did not trust GP confidentiality while 19.9%
said they were unclear of their legal rights to access care
(Table 5). Slightly fewer men of either sexual orientation
group reported difficulties overall. Among gay/bisexual men,
long waiting times were a problem for 40.1% who reported
difficulties, whereas 25.3% were unclear of their rights to
access care. For heterosexual men who reported problems,
language barriers presented difficulties for 27.7% and a quar-
ter (25.3%) were unclear of their rights to access care.
Travel expenses and prescription costs presented additional
barriers for those who funded this element of their care. The
cost of prescriptions (for all medication, not just Antiretrovi-
rals) resulted in delaying or forgoing medications for 8.3% of
women, 8.8% of heterosexual men and 4.9% of gay/bisexual
men. Around one in ten women (11.9%), 15.1% of heterosex-
ual men and 6.9% of gay/bisexual men reported missing
appointments due to travel costs (Table 5).
Access to primary care was varied across countries. In
Greece, Germany, Italy, the Netherlands and United Kingdom
>95% of respondents in one or more gender-related group
reported having a primary care physician or access to an
infectious disease unit (Table 6). In multivariable analysis,
access to primary care was associated with CCOR and immi-
gration status in all three groups. In addition, years since
migration and being on antiretroviral therapy remained signifi-
cantly associated with access to primary care among gay/bi-
sexual men.
There were no significant interactions between CCOR or
country of birth and any of the factors in the models selected
for any group (data not shown).
4 | DISCUSSION
This study provides valuable data about the barriers and facili-
tators to secondary HIV prevention and accessing primary
care for different migrant groups living with HIV in Europe. In
addition, we have shown that for migrant women and hetero-
sexual men, structural factors related to child-bearing or immi-
gration status have a strong association with access to HIV
testing. For migrant gay/bisexual men barriers to testing are
mainly related to sexual behavioural factors with bisexual men
and those with fewer partners less likely to have a previous
negative test. Access to primary care, an indicator of integra-
tion into health services, was found to be strongly associated
with current country of residence in all groups and immigra-
tion status among women and gay/bisexual men.
4.1 | Policy Implications
Our findings suggest that for migrant women and heterosex-
ual men, interventions that target sexual behaviour or other
individual-level lifestyle factors might not be particularly suc-
cessful in increasing the uptake of HIV testing. Rather, inter-
ventions that aim to address structural barriers could achieve
more in the effort to increase access to earlier and regular
testing. Large numbers in each group had attended primary
care in the two years prior to diagnosis, however, attendance
was not associated with the probability of having a negative
test before diagnosis, or was it associated with late diagnosis
(data not shown). The low proportion of individuals offered an
HIV test before diagnosis suggests that there are continued
missed opportunities for HIV testing, particularly in primary
care. Policies advocating opportunistic provider-initiated test-
ing, as provided in antenatal services in much of Europe, have
Table 4. (Continued)
% (n/N) OR AOR 95% CI p value
Diagnosed with STI before HIV diagnosis <0.001
No 75.2 (354/471) 1.00 1.00 –
Yes 95.1 (294/309) 6.42 4.41 2.42 to 8.03
Sexual orientation 0.002
Gay 85.4 (568/665) 1.00 1.00 –
Bisexual 69.6 (80/115) 0.37 0.43 0.25 to 0.74
OR, odds ratio; AOR, adjusted odds ratio; 95% CI, 95% confidence interval; ART, antiretroviral therapy; STI, sexually transmitted infection.
aAfter final model selection. All models adjusted for factors listed in the model.
bExcluded from multivariable analysis because of perfect prediction (separation).
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been successful in increasing HIV testing and diagnosing
women at earlier stages of infection [18] and a similar
approach could work in primary care. Previous studies have
shown that the introduction of routine, rapid or point-of-care
testing in primary care is feasible and acceptable, especially
among migrant or black and minority ethnic communities
[19-22]. In addition, there may still be missed opportunities
for testing in antenatal care as less than half of those who
attended recalled HIV being mentioned during their visit. It is
possible that women were unaware of routine opt-out testing.
However, as multivariable analysis indicated that previous neg-
ative testing was associated with post-migration antenatal
care these findings are difficult to interpret.
Missed opportunities are also likely to shape the HIV epi-
demic among migrant gay and bisexual men. Findings from this
study support others that suggest that health promotion spe-
cialists may wish to consider targeted HIV testing interven-
tions with men who identify as bisexual or who have low
numbers of sexual partners [23-26]. Although the vast major-
ity of gay/bisexual men had previously tested negative for
HIV, over half had seroconverted within two years of their
last negative test. This suggests there remain unmet HIV pre-
vention needs, particularly about safer sex and condom use in
this group, as highlighted by other studies [23-27]. Policymak-
ers might need to expedite access to biomedical interventions
such as Pre-exposure Prophylaxis (PrEP) that have been
shown to be highly effective in European contexts [28,29] for
migrant MSM and focus combination prevention efforts on
this group in an effort to reduce seroconversion. Incorporating
migration status with transmission risk in national surveillance
data will enhance the ability to monitor and address HIV pre-
vention needs for migrant MSM. In this study, we have shown
that the main barriers to accessing ongoing healthcare are
similar to those expressed by patients living with other
chronic conditions, for example, long waiting times and difficul-
ties with appointments [30,31]. This is perhaps to be expected
as the mechanisms of accessing care are well documented as
barriers, particularly among migrants who have competing
interests which deprioritize health concerns [10].
Immigration legislation differs across Europe and changes to
health policy affecting migrants frequently occur [32,33].
While all countries in this survey currently provide free ART
for at least some migrants, only the United Kingdom provides
all migrants with free ART regardless of their immigration sta-
tus (see OptTest for more details [33]). However, even in the
United Kingdom such affordable healthcare does not extend
to other health conditions, which may present challenges for
migrants living with multimorbidities.
Within this survey a substantial proportion of respondents
were not taking ART, possibly because the data from this
study were collected before updated European HIV Treatment
Guidelines recommended immediate ART initiation irrespec-
tive of CD4 count [34]. The impact of the new guidelines on
the uptake of ART in this population cannot be known from
this study and further research is needed to establish if there
remains a substantial (16 to 31%) deficit in uptake of ART,
particularly among migrant gay and bisexual men, and whether
high treatment costs are a barrier to ART initiation or
Table 5. HIV treatment characteristics of aMASE clinic survey respondents, by gender (men separated by sexual orientation)
Women Heterosexual men Gay/bisexual men
Most recent CD4 cell count ≥350 cells mm3 (n = 2011) 494 (76.8) 282 (65.4) 814 (86.9)
Undetectable viral load (<50 copies/mL) (n = 1540)a 409 (77.2) 290 (75.9) 489 (77.9)
Currently not on HIV treatment (n = 2090)b 105 (16.0) 40 (9.0) 312 (31.6)
Reason not on HIV treatment (n = 457)
Doctor’s advice or newly diagnosed 90 (85.7) 33 (82.5) 276 (88.5)
High cost or otherwise inaccessible 3 (2.9) 0 (0.0) 15 (4.8)
Fear of side effects or other difficulties taking medication 9 (8.6) 5 (12.5) 25 (8.0)
Other reason 7 (6.7) 3 (7.5) 16 (5.1)
Access to primary care (n = 2076) 552 (85.1) 369 (83.5) 833 (84.6)
Government-funded HIV treatment and care (n = 972)b,c 244 (78.2) 162 (78.6) 319 (70.3)
Experienced difficulties with health service in CCOR (n = 2093) 211 (32.3) 132 (29.9) 272 (27.7)
No GP/Health card/insurance (n = 628) 33 (15.3) 18 (13.1) 58 (20.9)
Unclear of rights to access medical care (n = 629) 43 (19.9) 35 (25.5) 70 (25.3)
Long waiting times for an appointment/in the clinic (n = 628) 72 (33.3) 29 (21.2) 111 (40.1)
Does not trust the GP confidentiality (n = 628) 48 (22.2) 31 (22.6) 37 (13.4)
Difficulty communicating with staff because of language differences (n = 628) 55 (25.5) 38 (27.7) 38 (13.7)
Difficulty negotiating healthcare system (e.g. finding GP, payment, travel) (n = 629) 22 (10.2) 13 (9.5) 31 (11.2)
Missed clinical appointments because of travel expenses (n = 2071) 77 (11.9) 66 (15.1) 68 (6.9)
Delayed/forwent medication because of prescription costs (n = 2078)d 54 (8.3) 39 (8.8) 48 (4.9)
Data are n (%).CCOR, Current Country of Residence.
aOnly those on antiretroviral therapy (ART).
bTested as an independent predictor in univariate analysis.
cExcludes co-pays.
dIncludes medicines other than antiretroviral therapy.
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Table 6. Factors associated with access to primary carea among women, heterosexual men and gay/bisexual men living with diag-
nosed HIV and attending HIV clinics in Europe
% (n/N) OR AOR 95% CI p value
Women (N = 409)
Current country of residence <0.001
Belgium 81.5 (88/108) 0.38 0.42 0.17 to 1.04
Greeceb 98.5 (65/66) – – –
Germanyb 80.0 (8/10) – – –
Italyb 100.0 (35/35) – – –
Netherlandsb 100.0 (20/20) – – –
Portugal 54.8 (46/84) 0.10 0.09 0.04 to 0.21
Spain 92.1 (140/152) 1.00 1.00 –
Switzerland 66.2 (43/65) 0.17 0.22 0.09 to 0.56
United Kingdomb 98.2 (107/109) – – –
Age (years) 0.129
18 to 24 71.4 (20/28) 0.69 0.47 0.17 to 1.28
25 to 34 78.4 (120/153) 1.00 1.00 –
35 to 44 80.0 (108/135) 1.10 1.04 0.54 to 1.98
45 to 54 81.5 (53/65) 1.21 1.24 0.52 to 2.95
55+ 57.1 (16/28) 0.37 0.39 0.14 to 1.08
Region of birth 0.420
Africa 74.5 (190/255) 1.00 1.00 –
Latin America/Caribbean 86.9 (86/99) 2.26 0.90 0.39 to 2.06
Rest of World 61.5 (8/13) 0.55 0.35 0.09 to 1.34
Europe 78.6 (33/42) 1.25 0.66 0.25 to 1.70
Years resident in country 0.252
≤2 62.8 (27/43) 0.26 0.40 0.14 to 1.12
3 to 5 71.7 (91/127) 0.39 0.45 0.20 to 1.03
6 to 10 79.3 (88/111) 0.59 0.60 0.27 to 1.35
>10 86.7 (111/128) 1.00 1.00 –
Immigration status 0.028
Permanent residency 84.0 (178/212) 1.00 1.00 –
Temporary residency 68.1 (81/119) 0.41 0.41 0.22 to 0.79
Refugee/Asylum seeker/Unknown 74.4 (58/78) 0.55 0.56 0.26 to 1.21
Heterosexual men (N = 271)
Current country of residence 0.004
Belgium 63.3 (38/60) 0.25 0.34 0.14 to 0.85
Greeceb 96.3 (52/54) – – –
Germanyb 100.0 (9/9) – – –
Italyb 100.0 (23/23) – – –
Netherlandsb 90.5 (19/21) – – –
Portugal 72.1 (31/43) 0.37 0.24 0.09 to 0.61
Spain 87.4 (104/119) 1.00 1.00 –
Switzerland 65.3 (32/49) 0.27 0.22 0.09 to 0.56
United Kingdomb 95.3 (61/64) – – –
Age (years) 0.211
18 to 24 62.5 (5/8) 0.56 0.44 0.08 to 2.40
25 to 34 80.0 (56/70) 1.33 1.40 0.61 to 3.21
35 to 44 75.0 (75/100) 1.00 1.00
45 to 54 69.7 (46/66) 0.77 0.56 0.26 to 1.22
55+ 85.2 (23/27) 1.92 1.72 0.49 to 6.04
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Table 6. (Continued)
% (n/N) OR AOR 95% CI p value
Region of birth 0.572
Africa 68.9 (104/151) 1.00 1.00
Latin America/Caribbean 83.3 (50/60) 2.26 1.27 0.52 to 3.09
Rest of World 71.4 (10/14) 1.13 1.07 0.28 to 4.00
Europe 89.1 (41/46) 3.71 2.18 0.72 to 6.57
Years resident in country 0.879
≤2 64.3 (9/14) 0.38 1.11 0.28 to 4.45
3 to 5 57.4 (27/47) 0.29 0.72 0.28 to 1.88
6 to 10 77.4 (65/84) 0.72 0.87 0.39 to 1.95
>10 82.5 (104/126) 1.00 1.00
Immigration status 0.040
Permanent residency 84.9 (135/159) 1.00 1.00 ..
Temporary residency 67.7 (44/65) 0.26 0.40 0.18 to 0.88
Refugee/Asylum seeker/Unknown 55.3 (26/47) 0.22 0.34 0.13 to 0.92
Gay/bisexual men (N = 913)
Current country of residence <0.001
Belgium 75.6 (65/86) 0.40 0.31 0.11 to 0.86
Greeceb 96.4 (53/55) – – –
Germanyb 100.0 (12/12) – – –
Italyb 100.0 (5/5) – – –
Netherlands 94.9 (74/78) 2.38 1.62 0.43 to 6.12
Portugal 52.9 (27/51) 0.14 0.06 0.02 to 0.16
Spain 88.6 (365/412) 1.00 1.00 –
Switzerland 59.0 (36/61) 0.19 0.08 0.03 to 0.21
United Kingdom 87.1 (196/225) 0.87 0.55 0.24 to 1.26
Age 0.334
18 to 24 72.6 (61/84) 0.66 0.69 0.36 to 1.30
25 to 34 80.0 (308/385) 1.00 1.00 –
35 to 44 86.0 (257/299) 1.53 1.03 0.62 to 1.70
45 to 54 94.3 (115/122) 4.11 2.11 0.85 to 5.26
55+ 95.7 (22/23) 5.50 1.34 0.16 to 11.34
Region of birth 0.255
Africa 83.3 (55/66) 1.06 2.36 0.95 to 5.88
Latin America/Caribbean 82.4 (371/450) 1.00 1.00 –
Rest of World 85.7 (114/133) 1.28 1.49 0.74 to 3.00
Europe 84.5 (223/264) 1.16 1.13 0.63 to 2.01
Years resident in country <0.001
≤2 59.8 (58/97) 0.15 0.17 0.09 to 0.35
3 to 5 72.6 (127/175) 0.27 0.44 0.24 to 0.82
6 to 10 89.6 (250/279) 0.89 1.21 0.66 to 2.22
>10 90.6 (328/362) 1.00 1.00 –
Immigration status <0.001
Permanent residency 88.0 (639/726) 1.00 1.00 –
Temporary residency 70.2 (92/131) 0.33 0.48 0.28 to 0.85
Refugee/Asylum seeker/Unknown 57.1 (32/56) 0.15 0.21 0.10 to 0.45
Currently on ART 0.001
No 79.9 (231/289) 0.69 0.42 0.26 to 0.70
Yes 85.3 (532/624) 1.00 1.00 –
OR, odds ratio; AOR, adjusted odds ratio; 95% CI, 95% confidence interval; ART, antiretroviral therapy.
aAfter final model selection.
bExcluded from multivariable analysis because of perfect prediction (separation) or small numbers. All models adjusted for factors listed in the
table.
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adherence for migrants who are not entitled to free ART. To
highlight the benefits of HIV treatment, clinicians and policy-
makers should consider the enhanced promotion of campaigns
such as “Undetectable = Untransmittable” to migrants have
not received accurate and up-to-date information about the
risks of sexual transmission of HIV for those successfully on
ART [35,36].
Migration-specific barriers, such as language barriers and
difficulties understanding the legal rights to accessing health-
care, presented a problem for 20 to 25% of participants who
experienced difficulties, although this finding is likely to have
been underestimated (see below). These barriers may present
challenges to physicians providing complex ongoing HIV
healthcare. For example, language barriers could lead to poor
health literacy among patients and consequently impact on
the initiation of—and adherence to—ART as well as poten-
tially facilitating onward transmission [37]. While it is beyond
the scope of this survey to ascertain whether uncertainty sur-
rounding the legal rights to access care leads to poor clinic
attendance or adherence, other studies have shown that fear
of deportation has prevented individuals from seeking care
[10]. In addition, as some healthcare providers seek to normal-
ize HIV by shifting care aware from specialist services to gen-
eral practice, this study presents a timely understanding of
some of the potential barriers to such policies.
Finally, this study found that poverty may influence access to
ongoing care, with a substantial proportion of all groups report-
ing missing clinic appointments due to travel expenses and delay-
ing or foregoing medication due to prescription costs. Poverty
was especially prevalent among heterosexual men with over
20% reporting moderate or severe household hunger in the past
four weeks. Poverty is well recognized as being associated with
poorer engagement in care [38-41]. While tackling the overall
problem of economic inequality is beyond the capacity of service
providers, these impediments to care need to be recognized and
where possible support offered to help mitigate this barrier.
4.2 | Limitations
This study is not without its limitations [16]. The clinics and
the countries were not selected at random and as such this
is a convenience sample and therefore some of the preva-
lence estimates may have been over- or underestimated. In
particular, it is likely that access to primary care was overes-
timated in some countries, as by including “health cards” and
“infectious disease units” in our definition of primary care we
may not have been able to sufficiently distinguish between
family doctors/GPs and specialist care for HIV; therefore,
caution is urged when using these estimates in health ser-
vice planning. The proportions of respondents experiencing
difficulties accessing health services are likely to have been
underestimated, as those who experienced the greatest diffi-
culties would not have been available in clinic to be recruited
to the survey. It was assumed that those without a previous
negative HIV test had experienced barriers to HIV testing
up until the point of diagnosis. It is possible that some indi-
viduals had tested for the first time immediately after being
exposed to HIV risk. However, given that a large proportion
of participants were diagnosed late, it is likely that this previ-
ous negative testing is a suitable proxy for access to HIV
testing.
5 | CONCLUSION
Migrants are accessing healthcare in Europe prior to HIV
diagnosis. While many migrants had previously tested negative
for HIV, missed opportunities for earlier diagnosis persist
among all migrant groups. In gay and bisexual migrant men
many of who initially tested HIV negative in the receiving
country went on to acquire HIV at a later date. Interventions
to further expand testing outside of sexual health and antena-
tal settings are still required and these opportunities should
be linked with combination prevention measures such as
access to PrEP and treatment as prevention.
AUTHORS ’ AFF I L IAT IONS
1Institute for Global Health, University College London, London, United Kingdom;
2National Centre of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain;
3Department of Health and Socio-medical Sciences, University of Alcala, Alcala
de Henares, Madrid; 4Department of Infectious Diseases, CHU Saint-Pierre,
Brussels, Belgium; 5European AIDS Treatment Group; 6HIV Centre Frankfurt,
Germany; 7Department of Hygiene, Epidemiology& Medical Statistics, Medical
School, National and Kapodistrian University of Athens, Athens, Greece; 8Aca-
demic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands;
9Public Health Service of Amsterdam, the Netherlands; 10Faculty of Medicine,
University of Porto, Porto, Portugal; 11Lausanne University Hospital, Lausanne,
Switzerland; 12Unit for Infectious Diseases and Assistance, Coordination and Ter-
ritorial Integration for Migrants’ Emergency, Civico- Benfratelli Hospital, Palermo,
Italy; 13Royal Free London NHS Foundation Trust, London, England
COMPET ING INTERESTS
The authors of this manuscript have no competing interests to declare.
AUTHORS ’ CONTR IBUT IONS
JDA and FB initiated this project. All authors and contributors in acknowledge-
ments section were involved in data collection and exchange. IF carried out the
data analyses and drafted the initial manuscript. FB, JDA and AC were also
involved in analysis interpretation and contributed to the discussion and conclu-
sions. AC also provided statistical support. All authors contributed to the design
of the study, commented on the manuscript and approved the final draft.
ACKNOWLEDGEMENTS
FUNDING
This project has received funding from the European Union’s Seventh Frame-
work Programme for research, technological development and demonstration
under EuroCoord grant agreement n˚ 260,694. Ms Fakoya was funded by a
Doctoral Research Fellowship from the National Institute for Health Research.
The views expressed in this study are those of the author(s) and not necessarily
those of the NHS, the NIHR or the Department of Health. Additional funding
was received from: Gilead Sciences Europe Ltd.; NIHR Clinical Research Net-
work, UK; Foundation for AIDS Research and Prevention in Spain (FISPSE) Pro-
ject 361,036/10; Consortium of Biomedical Research in Epidemiology and
Public Health, Spain; Spanish HIV Research Network for Excellence (RD06/006
and RD12/0017/0018); FIPSE (Fundacion para la Prevencion de SIDA en
Espa~na) 361,036/10, Consortium of Biomedical Research in Epidemiology and
Public Health, Spain (CIBER). Research and Development Fund, Public Health
Service of Amsterdam; and the Swiss HIV Cohort study (project #727), sup-
ported by the Swiss National Science Foundation (grant #148,522) and by the
SHCS Research Foundation. No funder had any role in the study, writing of the
manuscript or decision to submit for publication
APPENDIX
This study would not be possible without the entire Work Package 14 collabo-
ration. The aMASE study team are as follows: A Aerssens, M Aguado, B Alimi, D
Alvarez-del Arco, O Anagnostou, J Anderson, A Antoniadou, M Arando, MJ
Fakoya I et al. Journal of the International AIDS Society 2018, 21(S4):e25123
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25123/full | https://doi.org/10.1002/jia2.25123
71
Barbera, H Barros, A Barthelemy, J Belda-Iba~nez, B Bertisch, J Bil, JR Blanco, K
Block, C Boesecke, M Boura, J Burgos, FM Burns, J Cabo, E Calabuig, L Camp-
bell, O Cardoso, W Claudia, N Clumeck, A Colucci, S Corrao, S Cuellar, J Cunha,
G Daikos, K Darling, J del Amo, J del Romero, P Dellot, M Dixneuf, P Domingo,
F Dronda, F Ebeling, A Engelhardt, B Engler, I Fakoya, J Farrell, J Fehr, M Feijo,
E Fernandez, E Fernandez Garcıa, T Fernandez, AL Fortes, J Fox, P Garcia de
Olalla, F Garcıa, P Gargalianos-Kakolyris, AF Gennotte, I Germano, G Gilleran, R
Gilson, S Goepel, HA Gogos, JL Gomez Sirvent, I Gountas, A Gregg, F Gutierrez,
MM Gutierrez, I Hermans, JA Iribarren, H Knobel, L Koulai, S Kourkounti, C La
Morte, T LeCompte, B Ledergerber, L Leonidou, MC Ligero, G Lindergard, S
Lino, MJ Lopes, A Lopez Lirola, M Louhenapessy, G Lourida, AM Luzi, F Maltez,
L Manirankunda, A Martın-Perez, L Martins, M Masıa, MG Mateu, P Meireles, A
Mendes, S Metallidis, S Mguni, A Milinkovic, JM Miro, K Mohrmann, S Monge,
M Montero, T Mouhebati, M Moutschen, M M€uller, C Murphy, C N€ostlinger, I
Oca~na, S Okumu-Fransche, G Onwuchekwa, JE Ospina, D Otiko, P Pacheco, R
Palacios, V Paparizos, V Papastamopoulos, V Paredes, N Patel, T Pellicer, A Pe~na,
N Petrosillo, A Pinheiro, J Pocas, A Portillo, F Post, F Prestileo, T Prestileo, M
Prins, P Prins, K Protopapas, M Psichogiou, F Pulido, J Rebollo, A Ribeirinho, I
Rıo, M Robau, JK Rockstroh, E Rodrigues, M Rodrıguez, C Sajani, M Salavert, R
Salman, N Sanz, G Schuettfort, G Sch€uttfort, C Schwarze- Zander, R Serr~ao, D
Silva, V Silva, P Silverio, A Skoutelis, C Staehelin, C Stephan, C Stretton, F Styles,
AF Sutre, S Taylor, B Teixeira, C Thierfelder, G Touloumi, O Tsachouridou, K
Tudor, E Valadas, M van Frankenhuijsen, M Vazquez, M Velasco Arribas, M
Vera, P Vinciana, A Volny-Anne, N Voudouri, JC Wasmuth, C Wengenroth, E
Wilkins, L Young, S Yurdakul, T Zafra Espinosa, W Zuilhof, F Zuure.
REFERENCES
1. Eurostat. Foreign citizens accounted for fewer than 7% of persons living in
the EU Member States in 2014. 2015. [cited 05 August 2018]. Available from:
http://ec.europa.eu/eurostat/en/web/products-press-releases/-/3-18122015-BP
Archived at Webcite http://www.webcitation.org/6zGT5b71A.
2. ECDC and WHO Europe. HIV/AIDS surveillance in Europe 2015. European
Centre for Disease Prevention and Control and WHO Regional Office for Eur-
ope: Stockholm; 2016.
3. Hernando V, Alvarez-del Arco D, Alejos B, Monge S, Amato-Gauci AJ, et al.
HIV infection in migrant populations in the European Union and European Eco-
nomic Area in 2007-2012; an epidemic on the move. J Acquir Immune Defic
Syndr. 2015;70(2):204–11.
4. del Amo J, Br€oring G, Hamers FF, Infuso A, Fenton K. Migrant health: epi-
demiology of HIV and AIDS in migrant communities and ethnic minorities in
EU/EEA countries. European Centre for Disease Prevention and Control: Stock-
holm; 2010.
5. Fakoya I, Alvarez-del Arco D, Woode-Owusu M, Monge S, Rivero-Montes-
deoca Y, Delpech V, et al. A systematic review of post-migration acquisition of
HIV among migrants from countries with generalised HIV epidemics living in
Europe: implications for effectively managing HIV prevention programmes and
policy. BMC Public Health, 2015;15:561.
6. Eurostat. Migration and migrant population statistics. 2013. [cited 11 Febru-
ary 2015]. Available from: http://epp.eurostat.ec.europa.eu/statistics_explained/in
dex.php/Migration_and_migrant_population_statistics (Archived by WebCite® at
http://www.webcitation.org/6cjwQxuZ1).
7. Thomas F. Migration and health: an introduction. In: Thomas F, editor. Hand-
book of migration and health. Cheltenham: Edward Elgar Publishing; 2016. p.
3–16.
8. Haour-Knipe M. Migration and HIV/AIDS in Europe. AIDS care, 21 Suppl
1:43–48.
9. Butler AR, Hallett TB. Migration and the transmission of STIs. In: Aral SO ,
Fenton KA, Lipshutz JA, editors. The new public health and STD/HIV prevention:
personal, public and health systems approaches. New York: Springer; 2013. p.
65–75.
10. Rechel B, Mladovsky P, Ingleby D, Mackenbach JP, McKee M. Migration
and health in an increasingly diverse Europe. Lancet. 2013;381(9873):1235–45.
11. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV
from persons aware and unaware that they are infected with the virus in the
USA. AIDS. 2006;20:1447–50.
12. Deblonde J, Sasse A, Del Amo J, Burns F, Delpech V, Cowan S, et al.
Restricted access to antiretroviral treatment for undocumented migrants: a bot-
tle neck to control the HIV epidemic in the EU/EEA. BMC Public Health.
2015;15:1228.
13. Evans AR, Hart GJ, Mole R, Mercer CH, Parutis V, Gerry CJ, et al. Central
and east European migrant men who have sex with men: an exploration of sex-
ual risk in the U.K. Sex Transm Infect. 2011;87(4):325–30.
14. Marcellin F, Carrieri MP, Peretti-Watel P, Bouhnik AD, Obadia Y, Lert F,
et al. Do migrants overreport adherence to highly active antiretroviral therapy?:
results from the French VESPA (ANRS-EN12) National Survey. J Acquir Immune
Defic Syndr. 2006;42(5):646–7.
15. Alvarez-del Arco D, Monge S, Azcoaga A, Rio I, Hernando V, Gonzalez C,
et al. HIV testing and counselling for migrant populations living in high-income
countries: a systematic review. Eur J Public Health. 2013;23(6):1039–45.
16. Fakoya I, Alvarez-Del Arco D, Monge S, Copas AJ, Gennotte AF, Volny-Anne
A, et al. Advancing Migrant Access to Health Services in Europe (AMASE): Pro-
tocol for a Cross-sectional Study. JMIR Res Protoc. 2016;5(2):e74.
17. United Nations. Composition of macro geographical (continental) regions,
geographical sub-regions, and selected economic and other groupings. 2014.
[cited 2016 Dec 23]. Available from: http://unstats.un.org/unsd/methods/m49/
m49regin.htm. (Archived by WebCite [Unicode_Missing] at http://www.webci
tation.org/6myTYsGQq).
18. Deblonde J, Claeys P, Temmerman M. Antenatal HIV screening in Europe: a
review of policies. Eur J Pub Health. 2007;17(5):414–8.
19. Prost A, Griffiths CJ, Anderson J, Wight D, Hart GJ. Feasibility and accept-
ability of offering rapid HIV tests to patients registering with primary care in
London (UK): a pilot study. Sex Transm Infect. 2009;85(5):326–9.
20. Leber W, McMullen H, Anderson J, Marlin N, Santos AC, Bremner S, et al.
Promotion of rapid testing for HIV in primary care (RHIVA2): a cluster-rando-
mised controlled trial. Lancet HIV. 2015;2(6):e229–35.
21. Ashby J, Braithewaite B, Walsh J, Gnani S, Fidler S, Cooke G. HIV testing
uptake and acceptability in an inner city polyclinic. AIDS Care. 2012;24(7):905–
9.
22. Gennotte AF, Semaille P, Ellis C, Necsoi C, Abdulatif M, Chellum N, et al.
Feasibility and acceptability of HIV screening through the use of rapid tests by
general practitioners in a Brussels area with a substantial African community.
HIV Med. 2013;14 Suppl 3:57–60.
23. Carvalho C, Fuertes R, Lucas R, Martins A, Campos MJ, Mend~ao L, et al.
HIV testing among Portuguese men who have sex with men–results from the
European MSM Internet Survey (EMIS). HIV Med. 2013;14 Suppl 3:15–8.
24. Fernandez-Davila P, Folch C, Ferrer L, Soriano R, Diez M, Casabona J. Who
are the men who have sex with men in Spain that have never been tested for
HIV? HIV Med. 2013;14 Suppl 3:44–8.
25. den Daas C, Doppen M, Schmidt AJ, Op de Coul E. Determinants of never
having tested for HIV among MSM in the Netherlands. BMJ Open 2016;6(1):
e009480.
26. Marcus U, Gassowski M, Kruspe M, Drewes J. Recency and frequency of
HIV testing among men who have sex with men in Germany and socio-demo-
graphic factors associated with testing behaviour. BMC Public Health.
2015;15:727.
27. Alvarez-Del Arco D, Fakoya I, Thomadakis C, Pantazis N, Touloumi G, Gen-
notte AF, et al. High levels of postmigration HIV acquisition within nine Euro-
pean countries. AIDS. 2017;31(14):1979–88.
28. Sagaon-Teyssier L, Suzan-Monti M, Demoulin B, Capitant C, Lorente N,
Preau M, et al. Uptake of PrEP and condom and sexual risk behavior among
MSM during the ANRS IPERGAY trial. AIDS Care. 2016;28 Suppl 1:48–55.
29. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-
exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD):
effectiveness results from the pilot phase of a pragmatic open-label randomised
trial. Lancet. 2016;387(10013):53–60.
30. Hill CJ, Joonas K. The impact of unacceptable wait time on health care
patients’ attitudes and actions. Health Mark Q. 2005;23(2):69–87.
31. Horigan G, Davies M, Findlay-White F, Chaney D, Coates V. Reasons why
patients referred to diabetes education programmes choose not to attend: a
systematic review. Diabet Med 2017;4(1):14–26.
32. AFP. Illegal immigrants to regain free healthcare. 2015.
33. OptTest. Barring The Way To Health|Legal and regulatory barriers which
impede the HIV care continuum in Europe. 2018 [cited 2018 Jan 29]. Available
from: http://legalbarriers.peoplewithhiveurope.org/en.
34. Ryom L, Boesecke C, Gisler V, Manzardo C, Rockstroh JK, Puoti M, et al.
Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for
the treatment of adult HIV-positive persons. HIV Med. 2016;17(2):83–8.
35. Prevention Access Campaign. HIV Undetectable = Untransmittable U=U.
2018. [cited 07 February 2018]. Available from: https://www.preventionaccess.
org/consensus Archived at: http://www.webcitation.org/6x3U4rqdF.
36. The Lancet HIV. U=U taking off in 2017. Lancet HIV. 2017;4(11):e475.
37. Kalichman SC, Benotsch E, Suarez T, Catz S, Miller J, Rompa D. Health lit-
eracy and health-related knowledge among persons living with HIV/AIDS. Am J
Prev Med. 2000;18(4):325–31.
38. Howarth A, Apea V, Michie S, Morris S, Sachikonye M, Mercer C, et al.
REACH: a mixed-methods study to investigate the measurement, prediction and
improvement of retention and engagement in outpatient HIV care. Health Serv
Deliv Res. 2017;5(13).
Fakoya I et al. Journal of the International AIDS Society 2018, 21(S4):e25123
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25123/full | https://doi.org/10.1002/jia2.25123
72
39. Burch L, Smith C, Anderson J, Sherr L, Rodger A, O’Connell R, et al. Socio-
economic factors and virological suppression among people diagnosed with HIV
in the United Kingdom: results from the ASTRA study. J Int AIDS Soc. 2014;17
(4 Suppl 3):19533.
40. Cavaleri MA, Kalogerogiannis K, McKay MM, Vitale L, Levi E, Jones S, et al.
Barriers to HIV care: an exploration of the complexities that influence engagement
in and utilization of treatment. Soc Work Health Care. 2010;49(10):934–45.
41. Koirala S, Deuba K, Nampaisan O, Marrone G, Ekstr€om AM; CAT-S group.
Facilitators and barriers for retention in HIV care between testing and treat-
ment in Asia-A study in Bangladesh, Indonesia, Lao, Nepal, Pakistan, Philippines
and Vietnam. PLoS ONE. 2017;12(5):e0176914.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article:
Additional File 1. Ethical approval for the aMASE (advancing
Migrant Access to Health Services in Europe) studies in each
participating country.
Additional File 2.
Figure S1. Current country of residence of male and female
respondents to the aMASE Clinic Survey. N = 2093 from 57
clinic sites (min, max patients 1, 148): Belgium 255, 4 clinics
(27, 148; Germany 31, 2 clinics (14, 17; Greece 175, 8 clinics
(1, 60) Italy 63, 2 clinics (20, 43); Netherlands 119, 3 clinics
(28, 51); Portugal 179, 7 clinics (5, 54); Spain 693, 18 clinics
(9, 141); Switzerland 177, 6 clinics (5, 42); United Kingdom
401, 7 clinics (21, 106).
Figure S2. Country of birth of male and female respondents
to the aMASE clinic survey. N = 2093 from 152 countries.
Brazil 146; Colombia 107; Nigeria 96; Ecuador 74; Cameroon
59; Ghana 58; Venezuela 57; Romania 56; Italy 52; Guinea-
Bissau 49; Albania 43; Peru 39; Cuba 37; Argentina 36;
Dominican Republic 36; Congo (Kinshasa) 35; Portugal 35;
Poland 34; Russia 33; Spain 32; France 31; Guinea 30; Angola
28; Equatorial Guinea 27; Morocco 27; Ukraine 26; Cote
d’Ivoire 25; Zimbabwe 25; Cape Verde 24; United States of
America 23; Bulgaria 22; Eritrea 22; Ethiopia 20; United King-
dom 20; Georgia 19; Rwanda 19; Togo 19; Bolivia 17;
Mozambique 17; South Africa 17; Kenya 16; China 15; Para-
guay 15; Thailand 15; Germany 14; Mexico 14; Suriname 13;
Burundi 12; Philippines 12; Sierra Leone 12; Turkey 12; India
11; Chile 9; Malaysia 9; Serbia 9; Uruguay 9; Australia 8;
Canada 8; Honduras 8; Hungary 8; Malawi 8; Netherlands 8;
Senegal 8; Tanzania 8; Tunisia 8; Uganda 8; Benin 7; Burkina
Faso 7; Czech Republic 7; Iran 7; Jamaica 7; Lebanon 7; Pak-
istan 7; Armenia 5; Belgium 5; Cyprus 5; Indonesia 5; Kaza-
khstan 5; Liberia 5; Nicaragua 5; Sweden 5; Switzerland 5;
Uzbekistan 5; Finland 4; Greece 4; Hong Kong 4; Mali 4;
Mauritius 4; Moldova 4; Nepal 4; Sao Tome and Principe 4;
Trinidad and Tobago 4; Zambia 4; Austria 3; Congo (Brazzav-
ille) 3; Egypt 3; Estonia 3; Gambia, The 3; Ireland 3; Israel 3;
Japan 3; Latvia 3; Netherlands Antilles 3; Sri Lanka 3; Sudan
3; Vietnam 3; Afghanistan 2; Antigua and Barbuda 2; Bangla-
desh 2; Bosnia and Herzegovina 2; Botswana 2; Denmark 2;
Gabon 2; Guatemala 2; Iraq 2; Kosovo 2; Macedonia 2; Mada-
gascar 2; New Zealand 2; Norway 2; Panama 2; Seychelles 2;
Slovakia 2; Slovenia 2; Somalia 2; Taiwan 2; Algeria 1; Azerbai-
jan 1; Bahamas, The 1; Barbados 1; Belarus 1; Burma 1; Cen-
tral African Republic 1; Comoros 1; Croatia 1; Djibouti 1;
Dominica 1; El Salvador 1; Guyana 1; Haiti 1; Laos 1; Libya 1;
Lithuania 1; Mauritania 1; Niger 1; Oman 1; Swaziland 1; Syria
1; Tajikistan 1; Timor-Leste 1; Turkmenistan 1; United Arab
Emirates 1.
Additional File 3
Table S2. Sociodemographic characteristics of survey respon-
dents, by gender (men separated by sexual orientation)
Table S3. Characteristics of survey respondents by gender
(men separated by sexual orientation) at time of diagnosis
Table S4. HIV treatment characteristics of aMASE clinic sur-
vey respondents, by gender (men separated by sexual orienta-
tion)
Fakoya I et al. Journal of the International AIDS Society 2018, 21(S4):e25123
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25123/full | https://doi.org/10.1002/jia2.25123
73
